Abbott buys Chile's CFR Pharmaceuticals in $2.9bn deal
This article was originally published in Scrip
Abbott Laboratories has agreed to acquire the Chilean branded generics company CFR Pharmaceuticals for around $2.9bn. CFR's share price shot up 46% to CLP181.50 ($0.33) on the Santiago stock exchange in reaction to the news, which comes three months after CFR's own $1.3bn bid to buy the South African firm Adcock Ingram fell through in the face of local and shareholder opposition.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.